Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Lancet. Infectious Diseases (Print)

• Publication date

  2011-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1473-3099(11)70177-3PMID 21784708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials.

  2013cited by this paper
• Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration

  2013cited by this paper
• Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

  2011cited by this paper
• Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.

  2011cited by this paper
• The quality of safety reporting in trials is still suboptimal: survey of major general medical journals.

  2011cited by this paper
• Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

  2010cited by this paper
• Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease

  2010cited by this paper
• Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

  2010cited by this paper
• Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.

  2010cited by this paper
• In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections.

  2010cited by this paper
• The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence

  2010cited by this paper
• Bayesian mapping of pulmonary tuberculosis in Antananarivo, Madagascar

  2010cited by this paper
• A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections.

  2010cited by this paper
• Reporting bias in medical research - a narrative review

  2010cited by this paper
• Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin

  2010cited by this paper
• In defense of Pierre Louis who pioneered the epidemiological approach to good medicine.

  2009cited by this paper
• Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

  2009cited by this paper
• Tigecycline.

  2009cited by this paper
• Intra-abdominal infections.

  2009cited by this paper
• Therapeutic options for infections due to vancomycin-resistant enterococci

  2009cited by this paper
• Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline.

  2009cited by this paper
• Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.

  2009cited by this paper
• Tigecycline-induced acute pancreatitis: case report and literature review.

  2009cited by this paper
• The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

  2009cited by this paper
• Statistical considerations in meta-analysis.

  2009cited by this paper
• Treatment of nursing home-acquired pneumonia.

  2009cited by this paper
• New antibiotic agents for bloodstream infections.

  2008cited by this paper
• Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.

  2008cited by this paper
• Selective reporting in clinical trials: analysis of trial protocols accepted by The Lancet.

  2008cited by this paper
• Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

  2008cited by this paper
• [Skin and soft tissue infections: current therapeutic options].

  2008cited by this paper
• Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.

  2008cited by this paper
• Arcsine test for publication bias in meta‐analyses with binary outcomes

  2008cited by this paper
• A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

  2008cited by this paper
• The Efficacy and Safety of Tigecycline for the Treatment of Complicated Intra-Adominal Infections - The European Experience

  2008cited by this paper
• Overview of Tigecycline Efficacy and Safety in the Treatment of Complicated Skin and Skin Structure Infections - A European Perspective

  2008cited by this paper
• Tigecycline Versus Levofloxacin for the Treatment of Community-Acquired Pneumonia: European Experience

  2008cited by this paper
• A review of tigecycline--the first glycylcycline.

  2008cited by this paper
• Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.

  2008cited by this paper
• Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.

  2008cited by this paper
• Establishing the role of tigecycline in an era of antimicrobial resistance

  2008cited by this paper
• Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

  2008cited by this paper
• Tigecycline in critical care.

  2008cited by this paper
• Tigecycline: A Critical Update

  2008cited by this paper
• Rapid Development of Acinetobacter baumannii Resistance to Tigecycline

  2007cited by this paper
• In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp.

  2007cited by this paper
• Diagnosis and Treatment of Extended-Spectrum and AmpC β-Lactamase–Producing Organisms

  2007cited by this paper
• Intra-abdominal infections

  2007cited by this paper
• Clinical trial registration: looking back and moving ahead.

  2007cited by this paper
• Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections

  2007cited by this paper
• Early Experience with Tigecycline for Ventilator‐Associated Pneumonia and Bacteremia Caused by Multidrug‐Resistant Acinetobacter baumannii

  2007cited by this paper
• Infectious Diseases: Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus

  2007cited by this paper
• Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo-β-Lactamase-Producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program

  2007cited by this paper
• Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections

  2007cited by this paper
• Predictors of Efficacy and Health Resource Utilization in Treatment of Complicated Intra-abdominal Infections: Evidence for Pooled Clinical Studies Comparing Tigecycline with Imipenem–Cilastatin

  2007cited by this paper
• Clinical trial registration: looking back and moving ahead.

  2007cited by this paper
• Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.

  2006cited by this paper
• Tigecycline: a glycylcycline antimicrobial agent.

  2006cited by this paper
• Tigecycline (Tygacil): The First in the Glycylcycline Class of Antibiotics

  2006cited by this paper
• Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms.

  2006cited by this paper
• Tigecycline: a new glycylcycline antimicrobial

  2006cited by this paper
• Tigecycline: First of a New Class of Antimicrobial Agents

  2006cited by this paper
• Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam

  2005cited by this paper
• Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.

  2005cited by this paper
• The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

  2005cited by this paper
• The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

  2005cited by this paper
• Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline.

  2005cited by this paper
• Tigecycline: a new glycylcycline for treatment of serious infections.

  2005cited by this paper
• A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]

  2005cited by this paper
• Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

  2005cited by this paper
• Antimicrobial activity and pharmacokinetics/pharmacodynamics of the novel glycylcycline, tigecycline.

  2005cited by this paper
• Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.

  2005cited by this paper
• Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.

  2005cited by this paper
• Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.

  2004cited by this paper
• Trial registration: a great idea switches from ignored to irresistible.

  2004cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed.

  2002cited by this paper
• Meta-analysis, Simpson's paradox, and the number needed to treat

  2002cited by this paper
• Linezolid: The first of a new class of antimicrobial agents

  2002cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Treatment of Nursing Home‐Acquired Pneumonia

  1991cited by this paper
• A note on graphical presentation of estimated odds ratios from several clinical trials.

  1988cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• The Interpretation of Interaction in Contingency Tables

  1951cited by this paper

• Impact of Antibiotic Therapy with Ceftazidime Avibactam vs. Best Available Therapy in Adult Patients with Bacteremia Caused by Carbapenem-Resistant Enterobacterales

  2025cites this paper
• Hierarchical activation of resistance genes under tetracyclines selective pressure in complex microbial community.

  2025cites this paper
• Emergence of two novel tmexCD-toprJ subtypes mediating tigecycline resistance in the megaplasmids from Pseudomonas putida.

  2025cites this paper
• High prevalence of cefiderocol resistance in carbapenem-resistant Escherichia coli: a warning from multicenter clinical data in China.

  2025cites this paper
• Impact of VRE-active perioperative prophylaxis in liver transplant patients colonized by Vancomycin-Resistant Enterococci.

  2025cites this paper
• Binding assays enable discovery of Tet(X) inhibitors that combat tetracycline destructase resistance

  2025cites this paper
• Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy

  2025cites this paper
• Multiple Copies of Tigecycline Gene Cluster tmexC6D6-toprJ1b in Pseudomonas mendocina in a Swine Farm

  2025cites this paper
• Stabilization of tigecycline solutions during susceptibility testing of microorganisms by broth microdilution method

  2025cites this paper
• Population Pharmacokinetics of Tigecycline in Critically Ill Patients and Optimal Dosage Regimens With Dose Simulations Based on Infection Type and Renal Function

  2025cites this paper
• Safety profiles of doxycycline, minocycline, and tigecycline in pediatric patients: a real-world pharmacovigilance analysis based on the FAERS database

  2024cites this paper
• Coexistence of plasmid-mediated tmexCD2-toprJ2, blaIMP-4, and blaNDM-1 in Klebsiella quasipneumoniae

  2024cites this paper
• Comparing the Outcomes of Cefoperazone/Sulbactam-Based and Non-Cefoperazone/Sulbactam-Based Therapeutic Regimens in Patients with Multiresistant Acinetobacter baumannii Infections—A Meta-Analysis

  2024cites this paper
• Serum concentration threshold and risk factors of tigecycline-induced hypofibrinogenaemia in critically ill patients.

  2024cites this paper
• A rapid liquid chromatography-tandem mass spectrometry based method for the detection of Tet(X) resistance gene in Enterobacteriaceae

  2024cites this paper
• Isoniazid potentiates tigecycline to kill methicillin-resistant Staphylococcus aureus

  2024cites this paper
• The effect of triclosan on intergeneric horizontal transmission of plasmid-mediated tigecycline resistance gene tet(X4) from Citrobacter freundii isolated from grass carp gut.

  2024cites this paper
• Mediastinitis caused by an NDM-1 Escherichia coli in a child with Dacron® Sano shunt after pulmonary atresia with ventricular septal defect surgery treated with combination of aztreonam-avibactam.

  2024cites this paper
• Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis

  2024cites this paper
• Large-scale bacterial genomic and metagenomic analysis reveals Pseudomonas aeruginosa as potential ancestral source of tigecycline resistance gene cluster tmexCD-toprJ.

  2024cites this paper
• Interplay of multiple carbapenemases and tigecycline resistance in Acinetobacter species: a serious combined threat.

  2024cites this paper
• Emergence of plasmid-mediated high-level tigecycline resistance gene tet(X4) in Enterobacterales from retail aquatic products.

  2024cites this paper
• Molecular mechanisms of tigecycline-resistance among Enterobacterales

  2024cites this paper
• The ISVsa3-ORF2-abh-tet(X4) circular intermediate-mediated transmission of tigecycline resistance in Escherichia coli isolates from duck farms

  2024cites this paper
• Co-transfer of IncFII/IncFIB and IncFII plasmids mediated by IS26 facilitates the transmission of mcr-8.1 and tmexCD1-toprJ1

  2024cites this paper
• Risk Factors and Mortality Outcomes in Elderly Patients With Bloodstream Infections: A Retrospective Analysis

  2024cites this paper
• Emergence of novel tigecycline resistance gene tet(X5) variant in multidrug-resistant Acinetobacter indicus of swine farming environments.

  2023cites this paper
• Emergence and Inter- and Intrahost Evolution of Pandrug-Resistant Klebsiella pneumoniae Coharboring tmexCD1-toprJ1, blaNDM-1, and blaKPC-2

  2023cites this paper
• The tigecycline resistance gene tetX has an expensive fitness cost based on increased outer membrane permeability and metabolic burden in Escherichia coli.

  2023cites this paper
• Development and Validation of a Nomogram for Predicting Tigecycline-Related Coagulopathy: A Retrospective Cohort Study

  2023cites this paper
• One global disseminated 193 kb high-risk hybrid plasmid harboring tet(X4), mcr or blaNDM threatening public health.

  2023cites this paper
• Comprehensive Analysis of Antimicrobial, Heavy Metal, and Pesticide Residues in Commercial Organic Fertilizers and Their Correlation with Tigecycline-Resistant tet(X)-Variant Genes

  2023cites this paper
• Pseudomonas Acts as a Reservoir of Novel Tigecycline Resistance Efflux Pump tmexC6D6-toprJ1b and tmexCD-toprJ Variants

  2023cites this paper
• Tétracyclines

  2023cites this paper
• A Visualized Mortality Prediction Score Model in Hematological Malignancies Patients with Carbapenem-Resistant Organisms Bloodstream Infection

  2023cites this paper
• Tigecycline Pharmacokinetic and Pharmacodynamic Profile in Patients with Chronic Obstructive Pulmonary Disease Exacerbation

  2023cites this paper
• Global distribution and genomic characteristics of tet(X)-positive Escherichia coli among humans, animals, and the environment.

  2023cites this paper
• Uncovering the diverse hosts of tigecycline resistance gene tet(X4) in anaerobic digestion systems treating swine manure by epicPCR

  2023cites this paper
• Identification of Plasmid-Mediated Tigecycline-Resistant Gene tet(X4) in Enterobacter cloacae from Pigs in China

  2022cites this paper
• Impact of age group on bloodstream infection risk evaluation in immunosuppressed patients: a retrospective, single-centre, 5-year cohort study

  2022cites this paper
• Treatment of Hospital-Acquired Infections in Patients with Cirrhosis – New Challenges

  2022cites this paper
• Multiple Copies of Mobile Tigecycline Resistance Efflux Pump Gene Cluster tmexC2D2.2-toprJ2 Identified in Chromosome of Aeromonas spp.

  2022cites this paper
• The Prognostic Factors of Bloodstream Infection in Immunosuppressed Elderly Patients: A Retrospective, Single-center, Five-year Cohort Study

  2022cites this paper
• The Prognostic Factors of Bloodstream Infection in Immunosuppressed Elderly Patients: A Retrospective, Single-center, Five-year Cohort Study

  2022cites this paper
• Molecular mechanisms and genomic basis of tigecycline-resistant Enterobacterales from swine slaughterhouses.

  2022cites this paper
• In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria

  2022cites this paper
• Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant Klebsiella pneumoniae Strains

  2022cites this paper
• The Blood–Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults

  2022cites this paper
• Emergence of a Novel Plasmid-Mediated Tigecycline Resistance Gene Cluster, tmexCD4-toprJ4, in Klebsiella quasipneumoniae and Enterobacter roggenkampii

  2022cites this paper
• A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data

  2022cites this paper
• Prevalence and risk factors of tigecycline-induced liver injury: A multicenter retrospective study.

  2022cites this paper
• Tigecycline treatment causes a decrease in peripheral blood platelet

  2022influential citation
• Coexistence of tmexCD-toprJ, blaNDM-1, and blaIMP-4 in One Plasmid Carried by Clinical Klebsiella spp.

  2022cites this paper
• Mobile tigecycline resistance gene tet(X4) persists with different animal manure composting treatments and fertilizer receiving soils.

  2022cites this paper
• Intrathecal or Intraventricular Tigecycline Therapy for Central Nervous System Infection Associated with Carbapenem-Resistant Klebsiella pneumoniae

  2022cites this paper
• The Development of Third-Generation Tetracycline Antibiotics and New Perspectives

  2021cites this paper
• Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review

  2021cites this paper
• Prevalence, transmission, and molecular epidemiology of tet(X)-positive bacteria among humans, animals, and environmental niches in China: An epidemiological, and genomic-based study.

  2021cites this paper
• Swine manure facilitates the spread of antibiotic resistome including tigecycline-resistant tet(X) variants to farm workers and receiving environment.

  2021cites this paper
• Dissemination of the tet(X)-Variant Genes from Layer Farms to Manure-Receiving Soil and Corresponding Lettuce.

  2021cites this paper
• Targeting Reactive Oxygen Species Capacity of Tumor Cells with Repurposed Drug as an Anticancer Therapy

  2021cites this paper
• Plasmids Shape the Current Prevalence of tmexCD1-toprJ1 among Klebsiella pneumoniae in Food Production Chains

  2021cites this paper
• TCRM_A_302850 325..332

  2021cites this paper
• Distribution and genomic characterization of tigecycline-resistant tet(X4)-positive Escherichia coli of swine farm origin

  2021cites this paper
• Novel tigecycline resistance gene cluster tnfxB3-tmexCD3-toprJ1b in Proteus spp. and Pseudomonas aeruginosa, co-existing with tet(X6) on an SXT/R391 integrative and conjugative element.

  2021cites this paper
• First Report of Coexistence of blaSFO–1 and blaNDM–1 β-Lactamase Genes as Well as Colistin Resistance Gene mcr-9 in a Transferrable Plasmid of a Clinical Isolate of Enterobacter hormaechei

  2021cites this paper
• Extensively drug-resistant acinetobacter baumannii meningitis which successfully treated with tigecycline; a case report of preterm newborn

  2021cites this paper
• An Outbreak of β -Lactamase Klebsiella Pneumoniae Carbapenemase 2–Producing Klebsiella Pneumoniae Bacteremia in Hematology Patients

  2021cites this paper
• Tigecycline in the Treatment of Ventilator-Associated Pneumonia Due to Stenotrophomonas maltophilia: A Multicenter Retrospective Cohort Study

  2021cites this paper
• Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales: Risk Factors for Mortality, Antimicrobial Therapy and Treatment Outcomes from a Prospective Multicenter Study

  2021cites this paper
• Risk Factors for Tigecycline-Associated Hypofibrinogenemia

  2021cites this paper
• Antibiotic selection based on microbiology and resistance profiles of bile from gallbladder of patients with acute cholecystitis

  2021cites this paper
• Synergistic Antibacterial Effect of Casein-AgNPs Combined with Tigecycline against Acinetobacter baumannii

  2021cites this paper
• Differences in Bile Microbiology and Antibiotic Resistances between Liver Transplant Recipients and Non-Transplant Patients

  2021cites this paper
• Antimicrobial susceptibility testing and successful treatment of hospitalised patients with extensively drug-resistant Campylobacter jejuni infections linked to a pet store puppy outbreak

  2021cites this paper
• Histone-Like Nucleoid Structuring Protein Modulates the Fitness of tet(X4)-Bearing IncX1 Plasmids in Gram-Negative Bacteria

  2021cites this paper
• Characterization of Three Porcine Acinetobacter towneri Strains Co-Harboring tet(X3) and bla OXA-58

  2020cites this paper
• Tigecycline: Role in the Management of cIAI and cSSTI in the Indian Context

  2020cites this paper
• Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review

  2020cites this paper
• In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria

  2020cites this paper
• Is it time to move away from polymyxins?: evidence and alternatives

  2020cites this paper
• Emergence of tigecycline- and eravacycline-resistant tet(X4)-producing Enterobacteriaceae in the gut microbiota of healthy Singaporeans.

  2020cites this paper
• Emerging High‐Level Tigecycline Resistance: Novel Tetracycline Destructases Spread via the Mobile Tet(X)

  2020cites this paper
• Molecular Characterization of an IncFIIk Plasmid Co-harboring blaIMP–26 and tet(A) Variant in a Clinical Klebsiella pneumoniae Isolate

  2020cites this paper
• Tigecycline: pharmacological concerns and resistance

  2020cites this paper
• Preliminary view of the global distribution and spread of the tet(X) family of tigecycline resistance genes.

  2020cites this paper
• Tigecycline therapy in pediatric patients with multidrug resistant bacteremia.

  2020cites this paper
• Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients

  2020cites this paper
• Uso compasional de tigeciclina intraventricular en pacientes con ventriculitis causada por Enterococcus faecium. Reporte de seis casos pediátricos

  2020cites this paper
• High-Dose Tigecycline in Elderly Patients with Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii in Intensive Care Unit

  2020cites this paper
• How to manage KPC infections

  2020cites this paper
• Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis

  2020cites this paper
• Carbapenem-Sparing Strategies for ESBL Producers: When and How

  2020cites this paper
• MDR Infections in the ICU

  2020cites this paper
• Outbreak of carbapenemase-producing (NDM-1 and OXA-48) and colistin-resistant Klebsiella pneumoniae ST307, north-east Germany, 2019

  2019cites this paper
• Complete Nucleotide Sequence of a Novel Plasmid Bearing the High-Level Tigecycline Resistance Gene tet(X4)

  2019cites this paper
• Novel Plasmid-Mediated tet(X5) Gene Conferring Resistance to Tigecycline, Eravacycline, and Omadacycline in a Clinical Acinetobacter baumannii Isolate

  2019cites this paper
• Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis.

  2019cites this paper
• Evaluation of the ratio of the estimated area under the concentration-time curve to minimum inhibitory concentration (estimated AUIC) as a predictor of the outcome for tigecycline treatment for pneumonia due to multidrug-resistant bacteria in an intensive care unit.

  2019cites this paper
• Carbapenemases in Enterobacteriaceae: Detection and Antimicrobial Therapy

  2019cites this paper